Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

PURPOSE: The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachy, Emmanuel, Seymour, John F., Feugier, Pierre, Offner, Fritz, López-Guillermo, Armando, Belada, David, Xerri, Luc, Catalano, John V., Brice, Pauline, Lemonnier, François, Martin, Alejandro, Casasnovas, Olivier, Pedersen, Lars M., Dorvaux, Véronique, Simpson, David, Leppa, Sirpa, Gabarre, Jean, da Silva, Maria G., Glaisner, Sylvie, Ysebaert, Loic, Vekhoff, Anne, Intragumtornchai, Tanin, Le Gouill, Steven, Lister, Andrew, Estell, Jane A., Milone, Gustavo, Sonet, Anne, Farhi, Jonathan, Zeuner, Harald, Tilly, Hervé, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823890/
https://www.ncbi.nlm.nih.gov/pubmed/31339826
http://dx.doi.org/10.1200/JCO.19.01073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823890/
https://www.ncbi.nlm.nih.gov/pubmed/31339826
http://dx.doi.org/10.1200/JCO.19.01073

Ejemplares similares